Légaré N, Grégoire C-A, De Benedictis L, Dumais A. Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. Med Hypotheses. 2013;80(6):689-91. DOI: 10.1016/j.mehy.2012.12.024. PubMed PMID: 23490199.
Gaertner I, Gaertner HJ, Vonthein R, Dietz K. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol. 2001;21(3):305-10. PubMed PMID: 11386494.
Liu HC, Chang WH, Wei FC, Lin SK, Lin SK, Jann MW. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit. 1996;18(2):200-7. PubMed PMID: 8721285.
Carrillo JA, Herraiz AG, Ramos SI, Benítez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol. 1998;18(4):311-6. PubMed PMID: 9690697.
Ng CH, Chong S-A, Lambert T, Fan A, Hackett LP, Mahendran R, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol. 2005;20(3):163-8. PubMed PMID: 15812267.
Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry. 1994;55 Suppl B:133-6. PubMed PMID: 7961557.
Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol. 1993;13(6):383-90. PubMed PMID: 8120151.